NCT06508307View on ClinicalTrials.gov

A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

June 30, 2026

Conditions
SarcomaCervical CancerColon CancerLung CancerOvarian CancerPancreatic CancerHepatocellular CarcinomaBreast CancerGastric Cancer
Interventions
BIOLOGICAL

A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors

The maximum number of lesions that each participant is allowed to inject at one time is two.

Trial Locations (1)

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

GONGCHU Biotechnology Co., Ltd

OTHER